0928.Hk
0928.HK operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
Business. 0928.HK operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
0928.HK operates in the healthcare sector, focusing on biotechnology and providing healthcare services and equipment.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.01, indicating a conservative leverage position. However, the company reported a negative operating cash flow of -HKD 322,000 and a free cash flow of -HKD 46.6 million, suggesting liquidity constraints despite a strong current ratio of 4.59. The negative net cash position after subtracting total debt raises concerns about short-term liquidity.
Profitability metrics show a significant underperformance relative to industry norms. The company reported a return on equity (ROE) of -21.31% and a return on assets (ROA) of -16.57%, both of which are negative and likely below the median for its industry. These figures indicate poor capital efficiency and operational performance.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks and limits the ability to offset losses in one area with gains in another.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. The negative operating and net income figures suggest a lack of profitability, which could hinder future expansion and investment in research and development.
The risk assessment highlights liquidity as a medium concern, with the company's negative net cash position after debt subtraction being a key flag. The dilution risk is assessed as low, with no significant dilution potential reported in the basic shares outstanding.
Recent events include the company's latest financial filing, which disclosed a substantial net loss and negative cash flows. No recent earnings call transcripts or other material events were identified in the available data.
- The company has a low debt-to-equity ratio but faces liquidity challenges due to negative operating and free cash flows.
- Profitability metrics are significantly negative, indicating poor performance relative to industry standards.
- Revenue is concentrated in a single segment, increasing exposure to sector-specific risks.
- Growth prospects are limited by current financial performance and lack of disclosed revenue growth.
- Liquidity risk is moderate, with dilution risk assessed as low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 0928.HK Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Mengyao WangExecutive Chairman of the Board